ABSTRACT
Purpose To assess myocarditis and pericarditis reporting rate as adverse drug reactions (ADRs) for the messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines authorized in Europe.
Methods Data on myocarditis and pericarditis related to mRNA COVID-19 vaccines (period: January 1, 2021 - February 11, 2022) were collected from the EudraVigilance database and combined with the European Centre for Disease Prevention and Control’s (ECDC) vaccination tracker database. The reporting rate was expressed as 1 million individual vaccinated-days with a corresponding 95% confidence interval (CI), and an observed-to-expected (OE) analysis was performed to check if there was an excess risk for myocarditis or pericarditis following mRNA COVID-19 vaccination.
Results The reporting rate of myocarditis per 1 million individual vaccinated-days in the study period was 17.27 (95% CI, 16.34-18.26) for the CX-024414 vaccine and 8.44 (95% CI, 8.18-8.70) for TOZINAMERAN vaccine. The reporting rate for pericarditis per 1 million individual vaccinated-days in the study period was 9.76 (95% CI, 9.06-10.51) for the CX-024414 vaccine and 5.79 (95% CI, 5.56-6.01) for TOZINAMERAN vaccine. The OE analysis showed that both vaccines produced a myocarditis standardized morbidity ratio (SMR) greater than 1, with the CX-024414 vaccine having a greater SMR than TOZINAMERAN. Regarding TOZINAMERAN, SMR for pericarditis was greater than 1 when considering the lowest background incidence, but smaller than 1 when considering the highest background incidence.
Conclusions Our results suggest an excess risk of myocarditis following the first dose of mRNA COVID-19 vaccine, but the relationship between pericarditis and mRNA COVID-19 vaccine remains unclear.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Only publicly available data are used in this study. This study was determined by Georgia Southern University's Institution Review Board (IRB) (H20364) to be exempt from full review under the G8 exemption category (Non-human subjects determination): This project does not involve obtaining information about living individuals or does not have direct interaction or intervention with individuals or their personal data so is not defined as human subjects research under human subjects regulations. ECDC Data on COVID-19 vaccination in the EU/EEA. Available at: https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea. Accessed 2/16/2022. EudraVigilance: European Database of suspected adverse drug reaction. European Medicines Agency. Available at: https://www.adrreports.eu/. Accessed 2/16/2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: The views expressed in the submitted manuscript are ours and not an official position of any institution or funder.
Source(s) of support: None
A minor edit was made to the abstract to clarify the meaning of a sentence.
Data Availability
All data produced in the present work are contained in the manuscript.
ABBREVIATIONS
- ADRs
- adverse drug reactions
- CI
- confidence interval
- COVID-19
- coronavirus disease 2019
- ECDC
- European Centre for Disease Prevention and Control
- EEA
- European Economic Area
- EMA
- European Medicines Agency
- EU
- European Union
- mRNA
- messenger ribonucleic acid
- OE
- observed-to-expected
- OR
- odds ratio
- PRAC
- Pharmacovigilance Risk Assessment Committee
- RNA
- ribonucleic acid
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SMR
- standardized morbidity ratio
